Related Experiment Videos
[Treatment of cardiac failure with angiotensin-converting enzyme inhibitors and diuretics]
G Deray1, F Martinez, C Jacobs
1Service de néphrologie Groupe hospitalier Pitié-Salpetrière, Paris.
Insights
Congestive cardiac failure (CCF) impacts kidney function, leading to fluid overload and electrolyte imbalances. Careful management with diuretics and ACE inhibitors, starting at low doses, is crucial for preventing adverse effects and improving outcomes.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Context:
- Congestive cardiac failure (CCF) significantly impacts renal perfusion, activating complex compensatory mechanisms.
- Advanced CCF (Stage IV) carries a poor prognosis with high mortality rates.
- Renal dysfunction in CCF creates a conflict between cardiac preservation and kidney-aggravated hemodynamic disturbances.
Purpose:
- To highlight the physiological conflict between cardiac and renal systems in congestive cardiac failure.
- To emphasize the critical role of diuretics and ACE inhibitors in managing CCF.
- To outline strategies for preventing adverse effects of these medications on renal function and electrolytes.
Summary:
- CCF causes blood flow redistribution, compromising kidneys and triggering compensatory mechanisms.
- This leads to a conflict where kidneys worsen hemodynamic issues (salt/water overload, hypokalemia, hypomagnesemia).
- Diuretics and ACE inhibitors are key, requiring low initial doses and close monitoring to prevent adverse renal and electrolyte effects, especially hyperkalemia with potassium-sparing agents.
Impact:
- Provides essential guidance for managing CCF patients, focusing on renal and electrolyte balance.
- Informs therapeutic strategies to mitigate risks associated with diuretics and ACE inhibitors.
- Aims to improve patient outcomes by preventing secondary complications of CCF treatment.
Abstract:
Congestive cardiac failure is characterised by redistribution of blood flow to the brain and the heart at the expense of the kidneys. The prognosis of this condition at its most advanced stage (stage IV) is poor with a mortality of about 50% at 5 years. The reduction of renal perfusion will lead to stimulation of all vasoconstrictor and anti-natiuretic mechanisms, and to a parallel activation of vasodilator and natiuretic systems. There is, therefore, a clear conflict of interest between the heart, which attempts to preserve its perfusion and function, and the kidneys which aggravate the haemodynamic disturbances by salt and water overload and the risk of arrhythmias due to hypokalaemia and hypomagnesaemia. The diuretics and ACE inhibitors are essential therapeutic classes for the treatment of congestive cardiac failure. The prevention of the secondary effects of diuretics and ACE inhibitors on renal function, serum sodium, potassium and magnesium concentrations, is based on an initial low dose prescription, the detection and correction of risk factors and strict clinical and biological surveillance. In order to avoid the risks of hyperkalaemia during the association of ACE inhibitor and diuretic therapy with a potassium sparing agent, the initial dose of these two drugs should be as low as possible.